Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
55.53 USD | +0.78% | +6.12% | +7.33% |
Mar. 20 | Sector Update: Health Care Stocks Ease Late Afternoon | MT |
Mar. 20 | Sector Update: Health Care Stocks Down Wednesday Afternoon | MT |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- The company's profit outlook over the next few years is a strong asset.
- The company is in a robust financial situation considering its net cash and margin position.
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- Sales forecast by analysts have been recently revised upwards.
- For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
- The opinion of analysts covering the stock has improved over the past four months.
Weaknesses
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 45.63 times its estimated earnings per share for the ongoing year.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+7.33% | 2.97B | B- | ||
-2.31% | 185B | C+ | ||
-3.20% | 105B | C | ||
-5.04% | 66.59B | A | ||
+0.20% | 54.66B | B- | ||
+17.29% | 47.78B | B- | ||
+4.06% | 41.26B | B+ | ||
+2.36% | 26.95B | A- | ||
+2.07% | 26.37B | B | ||
+12.96% | 24.8B | A- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- LIVN Stock
- Ratings LivaNova PLC